focus -WSS

focus

author：leisure time 2025-09-06 03:50:37 - browse：9

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Elizabeth Holmes on track for early release from her 11

leisure time

hotspot

WSS

Oak trusses raised to roof of fire

FDA clears AI tool for detecting skin cancer

Eli Lilly, Pfizer, and others want in on the online prescription market

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

New brain studies show LSD's effects on the brain in full color

Living with Fabry disease, a condition that causes chronic pain

explore

focus

hotspot

In Memoriam: Notable people who died in 2023

It's time to get medical device identifiers over the finish line

Psychedelics group wrestles with new pharma identity

California’s proposed $25 per hour health care minimum wage

Drug repurposing or repositioning? The language matters

N.Y. state detects polio case, first in the U.S. since 2013

Tori Bowie and the unacceptable rates of Black maternal death

How the political right came to back psychedelics to treat trauma

Tori Bowie and the unacceptable rates of Black maternal death

N.Y. state detects polio case, first in the U.S. since 2013

focus

Iowa House, Senate pass 6

Readout Newsletter: Merck, J&J, and long Covid

Eli Lilly, Pfizer, and others want in on the online prescription market

Threats against the LGBTQIA+ community intensifying: Department of Homeland Security

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Independent physicians launch a new lobbying group

leisure time

hotspot

hotspot

focus